EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

TOP ARTICLES

  • 3

    Quality by Design Is a Mindset, Not a Milestone

    Lakshmi

    Quality by Design has been embedded in European regulatory expectation for nearly two decades, yet it is still widely treated as a dossier section rather than an operating philosophy. This article exa...

press releases Read more...

BioMed X Relocates Global Headquarters to Heidelberg Innovation Park (hip) and Enters Partnership with BioLabs

BioMed X a leading innovation engine for pharma today announced the relocation of its global headquarters to LAB at Heidelberg Innovation Park hip together with the launch of a global partnership with BioLabs a leading provider of shared laboratory infrastructure for life science innovators

11th Edition Medical Device Project and Portfolio Management

Medical device organizations are under increasing pressure to deliver more innovation with fewer resources while navigating regulatory complexity rising development costs portfolio congestion and growing demands

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

Nxera Pharma Co Ltd Nxera or the Company TSE announces that its partner Neurocrine Biosciences Inc Neurocrine has received IND Acceptance from the US Food and Drug Administration

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWS Read more...

4basebio and Genezen Expand Collaboration on Synthetic DNA for Viral Vector Manufacturing

basebio PLC a specialist in enzymatically produced cellfree DNA for genetic medicines has expanded its collaboration with viral vector contract development and manufacturing organisation CDMO Genezen

Cronus Pharma Launches FDA-Approved Bioequivalent R

Cronus Pharma LLC has launched Robenacoxib Injection in the US offering an FDAapproved bioequivalent to ONSIOR robenacoxib Injection for veterinary use

Artis BioSolutions Launches mRNA and LNP Manufacturing Centre in Bilbao, Spain

Artis BioSolutions has launched its Genetic Medicines Centre of Excellence in Bilbao Spain expanding its development and manufacturing capabilities for genetic medicines

Lundbeck and EVERSANA Expand Partnership to Advance AI-Powered Commercialisation

Lundbeck a global pharmaceutical company focused on brain health and EVERSANA a provider of commercial services for the life sciences industry have announced a strategic partnership

Cambrex High Point Completes Regulatory Inspections to Support Commercial API Manufacturing

Cambrex a global contract development and manufacturing organisation CDMO has completed PreApproval Inspections PAIs at its High Point North Carolina facility by the US Food and Drug Administration FDA

ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for Hereditary Angioedema

ADARx Pharmaceuticals Inc has received Fast Track Designation from the US Food and Drug Administration FDA for onvuzosiran an investigational small interfering RNA siRNA therapy being developed to prevent attacks of hereditary angioedema HAE